Vistra Corp.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
18. Earnings Per Share
- EARNINGS PER SHARE
Basic earnings per share available to common stockholders are based on the weighted-average number of common shares outstanding during the period. Diluted earnings per share is calculated using the treasury stock method and includes the effect of all potential issuances of common shares under stock-based incentive compensation arrangements.
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| (in millions, except share data) | ||||
| Net income attributable to Vistra | $1,140 | $652 | $2,474 | $711 |
| Less cumulative dividends attributable to Series A Preferred Stock | (20) | (20) | (60) | (60) |
| Less cumulative dividends attributable to Series B Preferred Stock | (17) | (17) | (52) | (52) |
| Less cumulative dividends attributable to Series C Preferred Stock | (11) | (11) | (32) | (32) |
| Net income attributable to common stock — basic and diluted | $1,092 | $604 | $2,330 | $567 |
| Weighted average shares of common stock outstanding: | ||||
| Basic | 335,413,414 | 338,749,454 | 336,685,683 | 339,313,294 |
| Dilutive securities: Stock-based incentive compensation plan | 2,439,243 | 6,285,706 | 2,952,290 | 6,990,323 |
| Diluted | 337,852,657 | 345,035,160 | 339,637,973 | 346,303,617 |
| Net income per weighted average share of common stock outstanding: | ||||
| Basic | $3.26 | $1.78 | $6.92 | $1.67 |
| Diluted | $3.23 | $1.75 | $6.86 | $1.64 |
Stock-based incentive compensation plan awards excluded from the calculation of diluted earnings per share because the effect would have been antidilutive totaled 369,172 and 308 shares in the three months ended September 30, 2026 and 2025, respectively, and 260,464 and 103 shares for the nine months ended September 30, 2026 and 2025, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.